Breast cancer survivors must remain vigilant for recurrence signs, which can manifest locally, regionally, or distantly. New ...

While traditional induction therapy for newly diagnosed stage 2 myeloma often focuses on combinations of proteasome inhibitors, immunomodulatory drugs, and steroids, these newer immunotherapy classes ...

Researchers at Northwestern Medicine found that 65% of their lung cancer patients weren't eligible for screening. They were ...

Breast cancer is the most common cancer in women, so it's vital to know the signs and symptoms to look out for - and how to ...

Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug ...

When 59-year-old Betty died from pancreatic cancer, her family were left devastated by how quickly the disease took hold.

The Barbara Ann Karmanos Cancer Institute, along with cancer centers and other organizations nationwide, recognizes November ...

Drs Joseph Mikhael and Sigurdur Y. Kristinsson discuss whether it is time to screen for multiple myeloma and what we can ...

Johnson & Johnson (J&J) has received a positive recommendation from the UK’s National Institute for Health and Care ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...

Breast cancer is the most common cancer among women in Sri Lanka. Annually, out of approximately 37,000 newly diagnosed ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of ...